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Abstract Stroke prevention efforts typically focus on either
ischemic or hemorrhagic stroke. This approach is overly
simplistic due to the frequent coexistence of ischemic and
hemorrhagic cerebrovascular disease. This coexistence,
termed “mixed cerebrovascular disease”, offers a conceptual
frameworkthatappearsusefulforstrokepreventionstrategies.
Mixed cerebrovascular disease incorporates clinical and sub-
clinical syndromes, including ischemic stroke, subclinical
infarct, white matter disease of aging (leukoaraiosis), intrace-
rebral hemorrhage, and cerebral microbleeds. Reliance on
mixed cerebrovascular disease as a diagnostic entity may
assist in stratifying risk of hemorrhagic stroke associated with
platelet therapy and anticoagulants. Animal models of hem-
orrhagic cerebrovascular disease, particularly models of
cerebral amyloid angiopathy and hypertension, offer novel
means for identifying underlyingmechanisms and developing
focused therapy. Phosphodiesterase (PDE) inhibitors repre-
sent a class of agents that, by targeting both platelets and
vessel wall, provide the kind of dual actions necessary for
stroke prevention, given the spectrum of disorders that char-
acterizes mixed cerebrovascular disease.
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“The way out is through the door. Why is it that no one
will use this method?”
Confucius
Introduction
Stroke prevention efforts typically focus on either ischemic
stroke or hemorrhagic stroke. It is understood that ischemic
stroke prevention requires a comprehensive approach for the
variety of stroke risk factors that a patient may encounter.
Similarly, patients who have sustained hemorrhagic stroke
will have targeted efforts directed against the vascular risk
factor(s) thought to be most significant in the etiology of the
hemorrhage, with hypertension being the typical culprit.
A principal focus for attention in stroke prevention
involves medications that target various elements of coagu-
lation pathways. For prevention of ischemic stroke, platelet
anti-aggregant medications are a prime issue, as well as use
of anticoagulants. Some degree of avoidance of these same
medications is a frequent element of any clinical strategy for
prevention of hemorrhagic stroke.
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overly simplistic, because it tends to ignore the potential
for coexistence of both entities. This coexistence is obvious
in the presence of clinically evident intracerebral hemor-
rhage and ischemic stroke. But what happens when the
coexistence is not obvious? What strategies are available
when subclinical hemorrhagic or ischemic cerebrovascular
disease may be present in the same individual patient? Or
alternatively, when clinical and subclinical cerebrovascular
disease coexist in a given patient?
The usual and customary conceptual framework for
stroke, as used in stroke prevention efforts, begins to break
down when the entity of “stroke” is examined critically.
What kind of stroke are we trying to prevent, exactly? Is it
possible to successfully navigate between the apparent
extremes of hemorrhagic and ischemic cerebrovascular dis-
ease? It is the contention of this paper that these are the kinds
of questions that will define stroke prevention for the coming
decades of the 21st century. At the very least, a new concep-
tual framework for stroke seems worthy of consideration.
This paper will review a new framework for conceptualiz-
ing cerebrovascular disease. Mechanisms for hemorrhagic
stroke will be discussed, with an emphasis on cerebral amy-
loid angiopathy. A pathway will be proposed for simulta-
neously addressing the “opposing” tendencies of thrombosis
and hemorrhage as they may coexist in the same patient.
Mixed Cerebrovascular Disease: A New Conceptual
Approach
The concept of “mixed cerebrovascular disease” has been
proposed as a framework for better understanding stroke,
and for improving stroke prevention efforts [1]. Mixed
cerebrovascular disease incorporates clinical and subclinical
stroke with hemorrhagic and ischemic stroke. The clinical
stroke syndromes thus incorporate the typical variety of
presentations encountered, with intracerebral hemorrhage
and ischemic stroke subsets (small vessel disease, large
vessel disease, cardiogenic, other). Subclinical stroke syn-
dromes include silent ischemic stroke and cerebral micro-
bleeds. Cerebral white matter disease (of aging) is an
additional component of mixed cerebrovascular disease.
There are both strengths and weaknesses of this conceptual
approach. A principal benefit of characterizing a given patient
ashaving“mixed cerebrovasculardisease”isthatthe clinician
is immediately confronted with the fact that, going forward
with stroke prevention efforts, this patient will require a com-
plex strategy. Simply relying on “antiplatelet medications” for
prevention of cerebral infarction will be insufficent.
The principal weakness of this approach is that it may
simply be too inclusive. For example, cerebral white matter
changes are ubiquitous in the population of age 65 and
older, with more than 95 % of individuals showing at least
some white matter change on magnetic resonance imaging
(MRI) [2]. Only about one-third of these changes are prob-
ably sufficient to be characterized as “disease”, but the
gradation between normal and pathological change remains
unclear.
A similar problem may arise with the inclusion of cere-
bral microbleeds. Microbleeds are present in approximately
20 % of the population beginning at age 60, a proportion
that increases to nearly 40 % by age 80 [3]. Pathological
studies reveal a much higher prevalence over the age of 70
[4, 5], but it is unclear whether both MRI and neuropatho-
logical findings are demonstrating the same entity. Howev-
er, this difficulty may be surmounted by simply focusing on
the inclusion of MRI-demonstrable cerebral microbleeds,
using gradient echo or the more sensitive susceptibility-
weighted imaging sequences.
To summarize, the use of mixed cerebrovascular disease
as a conceptual and clinical framework appears feasible.
Inclusionofcerebralwhitematterdiseasemaybeproblematic.
Nevertheless, a characterization of stroke syndromes that
incorporates clinical and subclinical ischemic and hemorrhag-
ic disease may help quickly characterize the complexity of
many stroke patients.
Intracerebral Hemorrhage and Ischemic Stroke
Prevention: Platelet Therapy, Anticoagulants,
and Statins
The risk of hemorrhagic stroke is known to increase with
platelet therapy used for stroke prevention. For example, in
stroke prevention trials the use of aspirin increased hemor-
rhagic stroke by relative risk of 84 %, or 12 hemorrhagic
strokes per 10,000 persons [6]. This risk does not appear to
significantly change with use of the platelet anti-aggregant
clopidogrel [7]. However, combination treatment of aspirin
with clopidogrel significantly increases hemorrhagic stroke
risk beyond that encountered with clopidogrel alone [8]. In-
terestingly, addition of clopidogrel to aspirin does not appear
to increase hemorrhagic stroke risk above aspirin alone [9].
Anticoagulation represents the other principal strategy for
medical therapy in stroke prevention. Warfarin is the principal
oral anticoagulant utilized, and carries a well-known risk for
intracerebral hemorrhage. Prevention of cardiogenic stroke,
particularly atrial fibrillation, is the primary indication for
warfarin; in this population, the risk of intracerebral hemor-
rhage ranges from 0.3 % to 1 % annually [10].
Recent advances in oral anticoagulants have focused on
substantially reducing this risk. Compared to warfarin, both
the direct thrombin inhibitor dabigatran and the factor Xa
inhibitor rivaroxaban have significantly less risk of intrace-
rebral hemorrhage, while providing effective protection
S40 Transl. Stroke Res. (2012) 3 (Suppl 1):S39–S51against cardiogenic stroke [11, 12]. For dabigatran, the
annual risk of of intracerebral hemorrhage was 0.23–
0.30 %, compared to 0.74 % for warfarin, a risk reduction
of 70–77 % [11]. For rivaroxaban versus warfarin, risk of
intracerebral hemorrhage was 0.5 versus 0.7 events/100
patient years, a risk reduction of approximately one-third
[12]. It should be emphasized that these represent a reduc-
tion, but hardly an elimination, of risk of intracerebral
hemorrhage with the new oral agents.
Statins represent another major component of therapy for
prevention of ischemic stroke. The definitive clinical trial
demonstrating benefits of atorvastatin showed divergent
effects of the drug on ischemic versus hemorrhagic stroke
[13]. On high dose atorvastatin, risk of ischemic stroke
declined by 22 %, while risk of hemorrhagic stroke in-
creased by 66 % [13]. Further analysis showed that some
of this excess risk of hemorrhagic stroke originated from
patients who had entered into the trial after a hemorrhagic
stroke, and that risk of hemorrhagic stroke was not increased
among patients who entered the trial following large vessel
or cardiogenic stroke [14]. Nevertheless, risk of hemorrhagic
stroke was nearly fivefold higher among patients with small
vessel ischemic stroke, an increased risk that was even higher
thanthatencounteredinpatientswhohadenteredthetrialwith
hemorrhagic stroke [14].
To summarize, routine preventive treatment for ischemic
stroke generates a significant risk for hemorrhagic stroke.
This increased risk includes use of platelet therapy, anti-
coagulants, and statins. Classification of ischemic stroke
patients by risk for hemorrhagic stroke represents a potential
benefit of moving toward the conceptual framework of
mixed cerebrovascular disease.
Mixed Cerebrovascular Disease: Stratification
of Ischemic Stroke Patients for Hemorrhagic
Stroke Risk
Clinical management in stroke neurology relies on risk
stratification, some of which is systematically formalized.
The best known example of this is the scoring system based
on presence of congestive heart failure, hypertension, age,
diabetes, and prior stroke or transient ischemic attack
(CHADS2) for estimating stroke risk in patients with atrial
fibrillation [15]. Given the catastrophic nature of intracere-
bral hemorrhage, risk stratification focusing on avoidance of
this entity is clearly an attractive option. Mixed cerebrovas-
cular disease as a diagnostic entity would appear to provide
that alternative.
Multiple studies have demonstrated that presence of ce-
rebral microbleeds on MRI is clearly associated with intra-
cerebral hemorrhage. Microbleeds are present in an
estimated 68 % of patients with spontaneous intracerebral
hemorrhage [16]. This has been shown in subjects with
presumed cerebral amyloid angiopathy as well as chronic
hypertension [16]. Moreover, association between cerebral
microbleeds and intracerebral hemorrhage has been demon-
strated in patients with prior ischemic stroke [17] and in
subjects with recurrent intracerebral hemorrhage [18]. Cur-
rent perspectives on cerebral microbleeds incorporate the
understanding that cortical microbleeds reflect underlying
amyloid angiopathy, while deep hemisphere microbleeds
indicate the consequences of hypertensive vascular disease
[3].
A relationship between use of platelet medications and
microbleeds is to be expected, and in fact has been demon-
strated. Wong and colleagues first demonstrated that intra-
cerebral hemorrhage in aspirin users was more common in
patients with presence of cerebral microbleeds, particularly
when the microbleeds were more extensive [19]. In a larger,
longitudinal study of more than 1000 subjects aged 60 and
older, use of platelet medications was associated with ap-
proximately 70 % increased risk of cerebral microbleeds
[20]. In a study of recurrent intracerebral hemorrhage, extent
of microbleeds was associated with recurrent hemorrhage,
as was aspirin use [18]. Among patients with chronic
(>5 years) aspirin use, risk for cerebral microbleeds in-
creased more than fivefold [21].
Similar to the microbleeds-platelet therapy relationship,
warfarin use and microbleeds are substantially linked.
Among anticoagulated patients developing intracerebral
hemorrhage, presence of microbleeds was associated with
more than sevenfold increased risk of intracerebral hemor-
rhage [22]. Lee et al. demonstrated an even more dramatic
association, showing a more than 80-fold increased risk of
intracerebral hemorrhage in warfarin-treated patients with
cerebral microbleeds [23]. While a smaller study failed to
show an association between warfarin use and micro-
bleeds [24], meta-analysis confirmed a relationship between
microbleeds and warfarin use in patients with intracerebral
hemorrhage [25].
Another element that can be incorporated into risk strat-
ification for drug-induced intracerebral hemorrhage is pres-
ence of cerebral white matter disease of aging, also known
as leukoaraiosis. As noted previously, white matter changes
are ubiquitous in an aging population [2] but, when exces-
sive, show an important relationship to intracerebral hemor-
rhage in warfarin users. Smith et al carefully examined
extent of cerebral white matter disease in ischemic stroke
patients using warfarin [26]. The case control study demon-
strated a nearly 13-fold increased risk for intracerebral hem-
orrhage conferred by leukoaraiosis among patients on
warfarin [26].
Given the relationship between risk for intracerebral
hemorrhage and both microbleeds and white matter disease,
it is not surprising that an important relationship exists
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between leukoaraiosis and microbleeds has been reported
by numerous investigators. Kato et al reported a strong
correlation between number of microbleeds and extent of
periventricular white matter changes [27]. Lee et al. [28],
Naka et al. [29], Maia et al. [30], Gorner et al. [31], Gao et
al. [32], and Pettersen et al. [33] all reported significant
associations of varying strength between extent of micro-
bleeds and severity of leukoaraiosis. Presence of micro-
bleeds and leukoaraisosis both predict development of new
microbleeds after ischemic stroke [34] and risk of intracere-
bral hemorrhage is particularly high in patients with hyper-
tension, microbleeds, and leukoaraiosis [35].
The microbleed-white matter disease association has
been further delineated by Yamada et al. [36], who studied
the relationships between white matter disease, microbleeds,
and age. This is a particularly important issue, given the age-
dependence of both entities. However, in this study presence
of microbleeds was more closely associated with white matter
disease than with age [36]. Another intriguing finding was the
single report linking low cholesterol levels and microbleeds
[37], which may provide some insight into the increased risk
of hemorrhagic stroke risk with high dose atorvastatin [14].
To summarize, cerebral microbleeds are a marker for
increased risk of intracerebral hemorrhage. This includes
risk of spontaneous intracerebral hemorrhage and risk of
intracerebral hemorrhage associated with warfarin usage.
Presence of microbleeds appears to be associated with use
of platelet medications, and cerebral white matter disease of
aging (leukoaraisosis) and microbleeds are closely associated.
This latter relationship, between leukoaraiosis and micro-
bleeds, has been shown so consistently that a common under-
lying mechanism appears likely. This mechanism appears
most likely to be a microvascular origin [38].
Mechanisms of Intracerebral Hemorrhage:
Animal Models
In order to investigate the molecular and cellular mechanisms
involved in intracerebral hemorrhage, as well as develop
effective therapies, it is important to have animal models that
replicate the critical features of the human cerebrovascular
pathogenesis. Moreover, to develop effective therapies that
do not exacerbate one type of cerebrovascular disorder at the
expense of the other (mixed cerebrovascular disease), it is
imperative that experiments are performed in animal models
that replicate this conundrum. Because animal models of
ischemic stroke are so well-developed, we have chosen to
focusonmousemodelsthatdevelopspontaneouspathological
lesions that may complicate therapeutic intervention for
ischemic stroke, e.g., cerebral amyloid angiopathy and cere-
bral microhemorrhages, or by experimental manipulation to
induce hypertension, which can contribute to ischemic stroke
or intracerebral hemorrhage.
Robust amyloid-beta (Aβ) depositions in the walls of
arterial blood vessels can result to noncellular thickening
of the vessel wall that can be visualized by hematoxylin and
eosin staining. However, histochemical or anti-Aβ antibody
immunohistochemical staining are required to detect cere-
bral amyloid angiopathy (Fig. 1)[ 39]. Modest vascular Aβ
deposits, as well as capillary involvement, can only be
visualized by immunohistochemistry. Most of the human
mutant amyloid precursor protein (APP) transgenic mouse
models deposit parenchymal plaques but also develop vary-
ing degrees of cerebral amyloid angiopathy (Fig. 2)[ 39, 40].
Characterization of the vascular pathology shows prominent
accumulation of Aβ40 peptide, smooth muscle degenera-
tion and loss, and evidence of microhemorrhage, all of
which are found associated with human cerebral amyloid
angiopathy. Generally, the cerebral amyloid angiopathy has
been found in the larger cortical and meningeal vessels
reminiscent of cerebral amyloid angiopathy-type 2 observed
in humans. In 1999, Jucker and colleagues reported on their
APP23 transgenic mice, which were generated with human
APP751 with human double Swedish (Sw) mutation, which
enhances β-secretase cleavage [43, 44]. They utilized the
murine thymocyte differentiation antigen 1 (Thy-1 or CD90)
Thy-1.2 promoter to drive expression of the transgene in a
C57B/6 background. The mice overexpress APP sevenfold
and first show Aβ deposits at 6 months of age. They also
reported significant deposition of Aβ in the cerebral vascu-
lature that had striking similarities to that observed in human
aging and Alzheimer’s disease. Amyloid deposition oc-
curred preferentially in arterioles and capillaries and within
individual vessels showed a wide heterogeneity [41]. The
APP23 transgenic mice were the first to show that anti-
amyloid immunotherapy in older mice exacerbated both
cerebral amyloid angiopathy and microhemorrhages [42].
Another useful APP transgenic (Tg) model is the Tg2576
mouse (C57B/6-SJL) that express human APP695, which
also contains the Sw APP mutation. The transgene is driven
by the hamster prion protein gene promoter and Tg2576
mice express APP at 5.6 times more than wild-type mouse
APP. Old Tg2576 mice (18+ months) develop cerebral
amyloid angiopathy in the larger vessels such as leptome-
ningeal and pial, and develop spontaneous microhemorrh-
ages. The Tg2576 mouse model has been used extensively
to investigate age-related cerebral amyloid angiopathy de-
position and microhemorrhages, as well as anti-Aβ immu-
notherapy induced microhemorrhages (Fig. 3)[ 45–48].
There have been efforts to generate cerebrovascular
amyloid models in the absence of significant parenchy-
mal amyloid deposition. Transgenic mouse lines were
developed utilizing mutations within human Aβ that are
found in familial forms of cerebral amyloid angiopathy.
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familial cerebral amyloid angiopathy Dutch E22Q variant of
human Aβ in brain resulting in a model of significant
larger meningeal and cortical vesselcerebralamyloid angi-
opathy in absence of parenchymal amyloid plaques. There
was also smooth muscle cell degeneration, hemorrhages, and
neuroinflammation [49].
Another very useful transgenic model that deposits Aβ in
cerebral vessels is the Tg-SwDI (C57B/6; B line, Thy-1.2
promoter), which contains the human APP-Sw mutation, but
in addition contains two human vasculotropic mutations (the
Dutch and the Iowa mutations) in the Aβ sequence [50, 51].
This mouse (hemizygous) begins to develop microvessel
Aβ deposits, reminiscent of cerebral amyloid angiopathy-
type 1 in humans, at 4–5 months of age in several cortical
areas. As the mice age, the microvessel deposition becomes
more widespread, and copious diffuse deposits develop
throughout the cortex. The only glial activation in the cen-
tral nervous system in the Tg-SwDI mice is associated with
the vascular deposition of Aβ.
Interestingly, two recent reports have established the
feasibility of actually imaging cerebral microhemorrhages
in APP transgenic mouse models [52, 53]. Luo et al. [52]
reported on magnetic resonance imaging detection and time
course of cerebral microhemorrhages during passive immu-
notherapy in living amyloid precursor protein transgenic
mice. Beckmann et al. [53] used superparamagnetic iron
oxide particles to enhance the magnetic resonance imaging
detection of cerebral amyloid angiopathy-related micro-
vascular alterations in APP transgenic mouse models of
Alzheimer’sd i s e a s e .
As mentioned above, hypertension has long been under-
stood to cause ischemic strokes [54, 55] as well as intrace-
rebral hemorrhage [56, 57] and white matter disease [58]
that have been linked small vessel disease [59, 60]. More
recently, however, vascular risk factors such as hypertension
have been proposed to play multiple roles in shaping the
trajectory to dementia in the elderly [61]. Several prospec-
tive cohort studies have provided compelling data suggest-
ing that higher blood pressure levels are associated with an
increased risk for dementia in the elderly [62–65], and high
midlife blood pressure levels have been correlated with late-
life cognitive deficits [66]. Finally, with regard to risk for
dementia of the Alzheimer’s disease-type, data from the
Rotterdam Scan Study indicate that apolipoprotein E4 car-
riers are at increased risk for white matter lesions if they
have hypertension [67]. In summary, midlife hypertension
increases the risk for cognitive impairment [63, 68, 69], and
atrophy of the hippocampus [70, 71], white matter disease
[72], amyloid plaques, and vascular lesions [73].
Growing evidence indicates that hypertension-induced
vascular injury contributes to a chronic low-grade inflam-
matory process and that inflammation may play a significant
role in the pathogenesis of hypertension [74]. In vitro,
Fig. 1 Examples of cerebral
amyloid angiopathy in cortical
arteries in 24-month-old
Tg2576 mice detected by
staining with Thioflavine S,
which binds to fibrillar forms
of amyloid-beta (Aβ).
(Scale bar: 50 μm)
Fig. 2 Types of cerebral amyloid angiopathy pathology in two amy-
loid precursor protein (APP) transgenic (Tg) mouse models. a Punctate
amyloid-β40 (Aβ40) deposits (arrows) on microvessels of 12-month-
old APP transgenic mice with three human APP mutations, the Swed-
ish, Dutch and Iowa (Tg-SwDI; scale bar: 20 μm). b Cerebral amyloid
angiopathy Aβ40 deposit (arrows) in large penetrating artery in 20-
month-old Tg2576 mouse (bar: 100 μm). c Spontaneous microhe-
morrhages (arrow)i n2 40 month 0 old Tg2576 mouse, visualized
using Prussian blue staining. (Scale bar: 200 μm). Inset: A higher
magnification image (200×) of spontaneous microhemorrhages
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various adhesion molecules, chemokines, cytokines and
growthfactors,and ultimatelycontributes tocellproliferation,
hypertrophy and inflammation. Angiotensin II influences the
inflammatory response by increasing vascular permeability
via prostaglandins and vascular endothelial growth factor
[75], among other factors. Importantly, angiotensin II-
induced vascular inflammation is mediated through different
and countervailing vascular wall effectors via two angiotensin
II receptor (AT) subtypes (proinflammatory AT1 and anti-
inflammatory AT2) [74].
Chronic hypertension models resemble most key fea-
tures of small vessel disease, and share the major risk
factors of hypertension and age with human small vessel
disease. The most widely used model has been the stroke-
prone spontaneously hypertensive rat (SHRSP) [76]. Inter-
estingly, the SHRSP rat can develop both hemorrhagic
and ischemic strokes. However, genetic factors appear to
contribute to stroke susceptibility in SHRSP independent
of blood pressure [76]. None of the animal models fully
mimics all features of the human cerebrovascular disease.
The optimal choice of model depends on the aspect of
pathophysiology being studied [77]. For example, the
SHRSP rat model does not develop cerebral amyloid
angiopathy, and is not conducive to breeding with other
cerebrovascular models, which are rather limited in rats.
Hypertensive mouse models do not appear to develop
stroke spontaneously, although there is a report of spon-
taneous unilateral brainstem infarction in non-inbred Swiss
mice [78].
While APP transgenic mice have not been shown to
develop spontaneous ischemic stroke, there are several pub-
lications demonstrating increased susceptibility of these
animals to ischemic insult. In 1997, Zhang et al. [79] dem-
onstrated that middle cerebral artery occlusion produced
enlarged infarct volume and reduced cerebral blood flow
in Tg2576 mice compared with wild-type littermates; this
was attributed to diminished endothelium-dependent vascu-
lar reactivity. Koistinaho and colleagues [80] showed in-
creased susceptibility to brain ischemia in APP751 mice
overexpressing the 751-amino acid isoform of human APP,
and suggested that this was mediated by increased micro-
glial activation and inflammation. Recently, experimental
models based on angiotensin II infusion have been reported
to better replicate human diseases, such as postmenopausal
hypertension, preeclampsia, vascular remodeling, vascular
aging, and neovascularization [81]. Mechanisms that lead to
intracerebral hemorrhage during hypertension, however, re-
main poorly understood, in part because of a paucity of
experimental models of spontaneous intracerebral hemor-
rhage in mice [82].
The first experimental model of spontaneous intracere-
bral hemorrhage in hypertensive mice utilized double trans-
genic mice with overexpression of human rennin and human
angiotensinogen, treated with No-nitro-L-arginine methyl
ester (L-NAME), an inhibitor of nitric oxide synthase, and
high-salt diet [83, 84]. But because this model requires
crossing the two transgenic mouse lines, it is not easily
applied to other transgenic mouse models, such as many
APP transgenic mouse models. More recently, Heistad and
colleagues [82] developed an experimental model of
hypertension-induced intracerebral hemorrhage (acute and
chronic insult) that facilitates studies in genetically altered
mice. They suggested that acute hypertension, induced by
angiotensin II or norepinephrine, may be critical for sponta-
neous intracerebral hemorrhage during chronic hypertension,
possibly via oxidative stress and matrix metalloproteinase 9
(MMP-9) [82]. They induced chronic hypertension with an-
giotensin II using subcutaneously implanted mini-osmotic
pumps, and then delivered acute doses via subcutaneous
injections. The incidence of intracerebral hemorrhage and
levels of oxidative stress and MMP-9 were greater in mice
with acute hypertension produced by angiotensin II than by
norepinephrine. Another less aggressive hypertension proto-
col is the slow-pressor angiotensin II model of hypertension,
whichhasbeenvalidatedbyseveralgroups[75,85,86],andis
pertinent because this model of hypertension mimics essential
Fig. 3 The progression of cerebral amyloid angiopathy pathology in
amyloid precursor protein Tg2576 mice at 12, 15 and 24 months of age
(12, 15, and 24 m). Immunostaining is performed using an antibody
specific for Aβ40, which is the predominant amyloid peptide deposited
in cerebral amyloid angiopathy. Parenchyma- penetrating blood vessels
with amyloid angiopathy are noted by arrows. (Scale bar: 100 μm). A
lower magnification image (4×) of frontal cortex with extensive cere-
bral amyloid angiopathy is shown in the top right corner of 24-month-
old mouse
S44 Transl. Stroke Res. (2012) 3 (Suppl 1):S39–S51hypertension found in humans [87]. One constraint of this
typeof experimental approach is thelimitedduration,typically
4 weeks, that hypertension can be maintained with an Alzet
pump (www.alzet.com).
Recently we have begun to focus on mouse models of
mixed cerebrovascular pathology to address some of the
clinically relevant questions regarding therapeutic interven-
tion in these complicated cases. Our initial approach has
been to examine how cerebral amyloid angiopathy affects
hypertension-induced adverse changes in cerebral blood
vessels, together with how the associated increases in neuro-
inflammation may exacerbate microhemorrhages and larger
intracerebral hemorrhages. Furthermore, we speculate that
Aβ and tau pathology in Alzheimer’s disease transgenic
mouse models may also be amplified due to chronic hyper-
tension. In preliminary studies we have used both Heistad
and colleagues’ aggressive protocol, in which spontaneous
intracerebral hemorrhage occurs in wild-type mice when
exposed to acute and chronic hypertension [82], as well as
the somewhat milder slow-pressor angiotensin II model of
hypertension [74, 85, 86]. In preliminary studies using the
acute and chronic hypertension model we found that hyper-
tensive Tg2576 mice were more prone to develop intracere-
bral hemorrhages in response to hypertension than non-Tg
littermates. Regardless of whether the mice developed intra-
cerebral hemorrhages, there was robust inflammation and
increased vascular amyloid (Fig. 4] in the gray matter of
Alzheimer’s disease mouse models, showing that hyperten-
sion may affect gray as well as white matter in the brain.
Perhaps surprisingly, plasma Aβ40 levels have recently
been independently associated with small vessel disease
[88], and these results are consistent with a role for Aβ40
in producing disruption of vascular endothelial function [89,
90]. Age-related alterations in transport across the blood–
brain barrier, as well as a reduction in the efficacy of the
perivascular drainage pathway, have been proposed to ex-
plain enhanced accumulation of cerebral parenchymal and
vascular amyloid deposits in the elderly [91–95]. Modeling
suggest that vessel pulsations provide the force to drive
perivascular drainage, and age-related stiffening of arteries
has been hypothesized to reduce flow and thus enhancing
Aβ deposition in the central nervous system [94].
Another crucial area of investigation where animal mod-
els have been particularly useful is hemorrhagic transforma-
tion following ischemic strokes [96]. Cerebral hemorrhagic
transformation, which occurs in 30–40 % of all ischemic
strokes, is a highly complex phenomenon in which second-
ary hemorrhagic lesion(s) are produced with increased per-
meability of the blood–brain barrier, extravasation into
surrounding tissue, and exacerbation of the brain injury
[96]. Because hemorrhagic transformation has been linked
to reperfusion injury, the widespread use of thrombolytic
medications may further increase the incidence of secondary
hemorrhagic lesions in ischemic stroke patients [97, 98].
Animal models have been quite useful in identifying under-
lying mechanisms, triggers, and molecular pathways which
contribute to hemorrhagic transformation including inflam-
mation, oxidative stress, and matrix metalloproteinases as
potential facilitators of hemorrhagic transformation due to
their ability to disrupt the blood–brain barrier [96, 99].
Moreover, animal models have been instrumental in testing
potential therapies, such as statins, angiotensin receptor
antagonists, and minocycline, designed to reduce the inci-
dence of hemorrhagic transformation [100–102].
The important roles of hypertension [103–106] and hyper-
glycemia [107–109] in development of hemorrhagic transfor-
mation have been extensively investigated. Acute hypertension
can induce hemorrhagic transformation in embolic models
[103, 104], while chronic hypertension can provoke hemor-
rhagictransformationwiththrombolysis[105]. Inspontaneous-
ly hypertensive rats, hemorrhagic transformation has been
attributed to larger ischemic lesions and more blood–brain
barrier disruption and vasogenic edema [106]. Mechanisms of
hyperglycemia-induced hemorrhagic transformation include
increased oxidative stress, upregulation of MMP-9, and en-
hanced blood–brain barrier disruption, as observed in models
of diabetes and/or acute hyperglycemia [107–109]. Moreover,
the possible neuroprotective agent isofluorane has been
Fig. 4 Hypertension induced by chronic angiotensin II + No-nitro-L-
arginine methyl ester (L-NAME) treatment and acute angiotensin II
injections (HYP) increases cerebral amyloid angiopathy relative to
phosphate buffered saline (PBS) only-treated control 15-month-old
Tg2576 mice. Detection of cerebral amyloid angiopathy by immuno-
histochemical staining with an antibody specific for Aβ40. Note cere-
bral amyloid angiopathy involvement in the cortex of the hypertensive
Tg2576 mice (asterisks). (Scale bar: 200 μm)
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orrhagic transformation [110].
An example of how a mouse model can be used to
investigate clinically relevant issues of therapeutic interven-
tion in older stroke patients involved the use of tissue
plasminogen activator in APP23 transgenic mice. Winkler
et al. [111] reported that the intravenous administration of
tissue plasminogen activator in APP23 mice produces in-
creased cerebral amyloid angiopathy-associated microhe-
morrhages and can also generate subarachnoid and
parenchymal hematomas. They concluded that tissue plas-
minogen activator use, in the presence of cerebral amyloid
angiopathy, carries an increased risk for cerebral hemor-
rhage in mice. Moreover, they emphasized that more work
is needed on tissue plasminogen activator-induced hemor-
rhage and cerebral amyloid angiopathy in elderly patients
and in subjects with Alzheimer’s disease, in whom extensive
cerebral amyloid angiopathy is quite common [111].
While management of hypertension and atherosclerosis
can reduce the incidence of intracerebral hemorrhage, there
are currently no approved therapies for attenuating cerebral
amyloid angiopathy. Thus there is a critical need for new
strategies that improve blood–brain barrier function and
limit the development of cerebral amyloid angiopathy.
PDE Inhibitors, Stroke Prevention, and Mixed
Cerebrovascular Disease
Mixed cerebrovascular disease represents the Scylla and
Charybdis of modern stroke neurology. The stroke neurolo-
gist must navigate between the apparent extremes of ische-
mic and hemorrhagic processes. For the most part, the
patient will come to the attention of the neurologist with
symptoms suggesting ischemic stroke, and cerebral micro-
bleeds and white matter disease will be identified inciden-
tally. Given its relationship to hemorrhagic stroke, the
presence of cerebral microbleeds is particularly challenging.
An attractive therapeutic strategy for mixed cerebrovas-
cular disease is one that targets both the coagulation system
and the vessel wall. Platelet agents may be focused on
receptor antagonism, but inhibition of signal transduction
pathways is an important alternative strategy for inhibition
of platelet activation pathways. Inhibition of platelet signal
transduction can be achieved by manipulation of platelet
second messenger pathways and/or amplification of effects
of endothelial-derived molecules (e.g., prostacyclin and
nitric oxide) that activate cyclases producing elevated levels
of intracellular cyclic adenosine monophosphate (cAMP)
and cyclic guanosine monophosphate (cGMP) [112]. Impor-
tantly, cAMP pathways have well-described major roles in
development of the blood–brain barrier [113].
Platelet levels of cyclic nucleotides have critical regula-
tory function, so that elevated levels of cAMP and cGMP
interfere with all known platelet activation pathways [112].
Signaling of cyclic nucleotides is modulated by their hydro-
lysis by phosphodiesterases (PDEs), with the latter regulated
by any of the more than 60 isoforms of the eleven families
of PDE inhibitors [112]. Notably, the PDE inhibitors dipyr-
idamole and cilostazol (Fig. 5) have been shown to have
beneficial actions for ischemic stroke prevention [114–117].
However, neither drug has been considered a first-line agent
for stroke prevention efforts.
Dipyridamole, a relatively nonspecific PDE inhibitor with
effects on both PDE3 and PDE5 [112], has been shown
beneficial for the prevention of ischemic stroke, with stroke
risk reduction comparable to that seen with aspirin [114].
Dipyridamole is known to have dual actions, combining
platelet anti-aggregant effects and vessel wall protection
[118]. Platelet actions are generated by adenosine-mediated
effects,alongwithpotentiationoftheplateletanti-aggregatory
effects of prostacyclin and nitric oxide [118]. Dipyridamole
inhibits red blood cell uptake of adenosine, resulting in ele-
vated plasma adenosine leading to stimulation of platelet
adenylyl cyclase and increased platelet cAMP [112, 118].
Vessel wall protection effects of dipyridamole are produced
via anti-oxidative effects and by inhibition of platelet–mono-
cyte interactions [118].
Recent animal work has emphasized the potential for
dipyridamole in stroke prevention as well as treatment.
Phosphodiesterase (PDE) Inhibitors 
Dipyridamole
(non-specific PDE inhibitor)
Cilostazol 
(PDE3 inhibitor)
Fig. 5 Two phosphodiesterase
(PDE) inhibitors used for stroke
prevention efforts, cilostazol,
and dipyridamole
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produced reduction of infarct volume in a rat model of exper-
imental stroke [119]. In a study particularly relevant for the
treatment of mixed cerebrovascular disease, oral supplemen-
tation of dipyridamole, at clinically relevant doses, did not
worsencerebralmicroscopic hemorrhageina mouse modelof
cerebral amyloid angiopathy [120]. This was observed even
after accelerated development of microscopic hemorrhages
using immunotherapy in aged transgenic animals [120].
PDE3 has high affinity for both cAMP and cGMP, but
behaves as a relatively specific cAMP PDE due to its low
hydrolysis efficacy for cGMP [112]. Cilostazol, a specific
PDE3 inhibitor with both platelet and vessel wall effects,
has been shown effective for prevention of ischemic stroke
versus aspirin [112, 116, 117]. Cilostazol inhibits shear
stress-induced platelet activation as well as collagen-, adeno-
sine diphosphate (ADP)-, arachidonic acid-, and epinephrine-
induced platelet aggregation [112]. Nevertheless, in a stroke
prevention trial, hemorrhagic events (including intracerebral
hemorrhage) were reduced by more than one half in
cilostazol-treated patients compared to aspirin [117]. In a
placebo-controlled stroke prevention trial, cilostazol-treated
patients tended to have fewer intracranial hemorrhages than
placebo (four versus seven) [115]. However, more work is
needed in the evaluation of hemorrhagic events in clinical
trials using cilostazol as well as dipyridamole.
Vesselwalleffectsofcilostazolhavebeenshowninclinical
and preclinical studies. These include reports of reduction of
hemorrhagic conversion of ischemic events in murine models
of experimental stroke, an effect observed with and without
treatment with tissue plasminogen activator [121, 122]. In a
clinical study of patients with intracranial atherosclerosis,
cilostazol appeared to have beneficial effects against progres-
sion of the disorder [123]. Potential mechanisms of anti-
atherogeniceffectsofcilostazolincludemodulationofexpres-
sion of MMP-9 and tissue inhibitor of metalloproteinase-1
(TIMP-1) by monocytes-macrophages [124]. In vitro studies
have shown enhancement of endothelial barrier function and
protectiveeffects against injurywithcilostazolinpreparations
using human brain endothelial cells [125].
In summary, an attractive therapeutic strategy for mixed
cerebrovascular disease is one that utilizes agents acting on
both platelets and vessel wall. Several PDE inhibitors have
those dual actions. Dipyridamole and cilostazol have al-
ready been shown effective in ischemic stroke prevention
clinical trials and may be particularly useful for patients with
mixed cerebrovascular disease.
Conclusion
Mixed cerebrovascular disease consists of ischemic and
hemorrhagic phenomena, both clinically evident disease as
well as subclinical processes. Ischemic stroke, subclinical
infarct, and white matter disease of aging (or leukoaraiosis)
combined with intracerebral hemorrhage and cerebral
microbleeds constitute this entity. The incorporation of these
processes into a single entity creates a novel concept in
stroke diagnostics.
The treatment of mixed cerebrovascular disease presents
the stroke clinician with a profound dilemma. What is the
way out of this conundrum? Use of PDE inhibitors, com-
bining platelet and vessel wall effects, provides one possible
strategy. There are, no doubt, other approaches that will
become increasingly obvious in the coming decades.
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